Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. https://t.co/y9QPieV0py https://t.co/GzwntEJLve

• Voclosporin and Steroids in Lupus Nephritis | RheumNow

3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria, including abstracts POS0732 and OP0255. https://t.co/XD1EJW2nNE https://t.co/jALVfebb8t

• 3 Big Lupus Themes from EULAR 2024 | RheumNow

Belimumab’s Sustained Impact in Lupus SLE a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of morbidity including impact on quality of life. https://t.co/4Gf5SJN5FG https://t.co/LxCjLQkaYQ

• Belimumab’s Sustained Impact in Lupus | RheumNow

Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org

Does B Cell Depletion Matter? Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria. https://t.co/IjxGWWjoGD https://t.co/GwLjB4Z7ub

• Does B Cell Depletion Matter? | RheumNow

#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso

• https://twitter.com/Yuz6Yusof/status/1801929946215993345/photo/1

#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7

• https://twitter.com/Yuz6Yusof/status/1801887094282789134/photo/1

#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr

• https://twitter.com/Yuz6Yusof/status/1801868458436477322/photo/1

Recommendation for management of fatigue in people with rheumatic disease. Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it. I will also add yearly blood work including: 1- VitD 2-HBA1c and LDl 3-TsH. https://t.co/3QvPqMxZSN

• https://twitter.com/NoufAhmedAlham2/status/1801552667375751282/photo/1
• https://twitter.com/NoufAhmedAlham2/status/1801552667375751282/photo/1